【05/02更新】(株)シーティーエス［ＣＴＳ］【4345】に注目！？皆はどうする？掲示板の反応まとめ。

国土強靭化もさる事ながら、建設とセメント銘柄に続き、災害にも強い企業と思い先月からINしました(o^^o)
安心してずっと持っときます。

頑張れCTS !

The Wall Street Journal
@WSJ
After the SEC tried to get Elon Musk to be more careful when speaking in public
about Tesla's business prospects, the billionaire tweeted an apparent reference
to a s○x act: "SEC, three letter acronym, middle word is Elon's"
SEC（米証券取引委員会）がイーロン・マスクに、テスラの事業見通しについて公の場
で話す際にはより慎重になるよう求めようとしたところ、この億万長者は明らかに性○為
について言及したツイートをしました。"SEC、3文字の頭字語、真ん中の単語はElon's"

いやはや・・・(´・ω・｀)

急騰とかなくても、じわ上げで十分。一時的な上げより、息が長い安定相場が理想。
CTSの株主な事に大満足しています。経営陣のビジョン、株主を大切にする姿勢、素晴らしい。

GOVERNMENT OF NORWAY もこの半年で１８万株ほど買い増しして、大株主上位5番手につけていますね。ノルウェ－政府の運用機関が太鼓判を押しているようなものですから、買い＆ホールドで応援しますよ！

休み明けに期待します

同感です。
CAS様のコメントにも共感できます。

ここは、派手ではないですが、地道に増収増益増配を行なっており、長期放置投資家は安心して放置できます。

他方、煌びやかな業務を叩き出す会社ではないので、短期では向かない会社と感じます。

他業種で言えば、パンパシフィック、神戸物産などが似ていると思います。
お互い利回り的にはすでに良くないが、安定して10年先も預けられる企業。

1000未満ならば、長期の覚悟あれば損しない株価だと思います。

好決算出しても売られる中、ここは例外？

ダウ下がってるけど大丈夫なのかな？

5/6は寄り天で早抜け競争じゃない？

信用買もだぶついてるし。

22年3月末まで最低株価1000円は保証するということですね。業績が毎年上昇しているのだから当然のこと。1000円以下で空売りしてる人は一刻も早く買戻したいが、6日は買いが殺到し売買は成立しないかも。1000円では満足してない人は売らないし、すぐにでも1260円は超えて行くと思う。

玉切れ

参りました。

さすがに、来週は上がるでしょ

890資金切れかな？

機関？
個人？
まさか自社株買い？

なかなかやるな。

撃ち落としてやったわ。

China has halted work on 2 high-speed rail projects - concerned over local govt debt

Moody's says it expects Australian mortgage delinquency rates higher

19th of April, 2021
AXEL MARK Inc.
Axcelead, Inc.
AXEL MARK and Axcelead have Agreed to Cooperate in
Product Evaluation & Domestic Logistics of Molecular Diagnostics Field
AXEL MARK Inc. (President & CEO, Hiroshi Matsukawa, TSE Mothers:3624, “Axcel Mark”) and Axcelead, Inc.
(President & CEO, Tomoyuki Fujisawa, “Axcelead”) today announced that they have agreed on a collaborative
partnership in product evaluation & domestic logistics of molecular diagnostics field.
AXEL MARK has previously made the disclosure of "The 22nd Acquisition and Cancellation of Stock
Acquisition Rights and the 1st Notice Regarding Changes in Use of Funds for Unsecured Convertible Bonds
with Stock Acquisition Rights” on March 26 2021, announced about our new entry into the healthcare
business, and this press release is an announcement regarding to it. Please see the following materials for
the information on AXEL MARK's entry into the healthcare business.
○Disclosure on 26th March, 2021
https://contents.xj-
storage.jp/xcontents/AS02626/59834c81/8587/4459/9a33/c4a07164fcd9/140120210326485155.pdf
The market is undergoing rapid expansion due to the unprecedented global demand for COVID-19 testing
via molecular methods, but the other segments, including cancer and various infectious disease, are also
experiencing significant growth. The global market for molecular diagnostics is expected to reach to the value
of more than $12bn. by 2024. ※
“Molecular diagnostics” is the diagnostic and screening process of infectious disease, cancer, and genetic
disease by analyzing proteins and nucleic acid（DNA and RNA）molecules in tissue or body fluid.
Disease identification is being utilized not only in medical site but also in private companies and home
diagnosis as it leads to early detection and treatment of diseases, and new technologies are being actively
developed worldwide.
In addition to the conventional major chemical analysis equipment, reagents, and scientific service
companies, start-up companies are also promoting the development of new technology for molecular
diagnosis, and test kits with various features have been commercialized, and new products will continue to be
released in the market from now on.
Axcelead will evaluate promising new technologies in the field of molecular diagnosis of overseas ventures
that do not have commercial distribution to Japan, and AXEL MARK will acquire domestic commercialization
rights and develop appropriate business partners. We believe that this partnership can build the collaborative
value chain in the molecular diagnosis market.
Hereafter, both companies aim to contribute to improve people’s healthy life expectancy by promoting the
spread of new medical diagnosis technologies.
https://www.axcelead-hd.com/wp-content/uploads/2021/04/ENG_AXELMARK_AXCELEAD2021.04.19.pdf

19th of April, 2021
AXEL MARK Inc.
Axcelead, Inc.
AXEL MARK and Axcelead have Agreed to Cooperate in
Product Evaluation & Domestic Logistics of Molecular Diagnostics Field
AXEL MARK Inc. (President & CEO, Hiroshi Matsukawa, TSE Mothers:3624, “Axcel Mark”) and Axcelead, Inc.
(President & CEO, Tomoyuki Fujisawa, “Axcelead”) today announced that they have agreed on a collaborative
partnership in product evaluation & domestic logistics of molecular diagnostics field.
AXEL MARK has previously made the disclosure of "The 22nd Acquisition and Cancellation of Stock
Acquisition Rights and the 1st Notice Regarding Changes in Use of Funds for Unsecured Convertible Bonds
with Stock Acquisition Rights” on March 26 2021, announced about our new entry into the healthcare
business, and this press release is an announcement regarding to it. Please see the following materials for
the information on AXEL MARK's entry into the healthcare business.
○Disclosure on 26th March, 2021
https://contents.xj-
storage.jp/xcontents/AS02626/59834c81/8587/4459/9a33/c4a07164fcd9/140120210326485155.pdf
The market is undergoing rapid expansion due to the unprecedented global demand for COVID-19 testing
via molecular methods, but the other segments, including cancer and various infectious disease, are also
experiencing significant growth. The global market for molecular diagnostics is expected to reach to the value
of more than $12bn. by 2024. ※
“Molecular diagnostics” is the diagnostic and screening process of infectious disease, cancer, and genetic
disease by analyzing proteins and nucleic acid（DNA and RNA）molecules in tissue or body fluid.
Disease identification is being utilized not only in medical site but also in private companies and home
diagnosis as it leads to early detection and treatment of diseases, and new technologies are being actively
developed worldwide.
In addition to the conventional major chemical analysis equipment, reagents, and scientific service
companies, start-up companies are also promoting the development of new technology for molecular
diagnosis, and test kits with various features have been commercialized, and new products will continue to be
released in the market from now on.
Axcelead will evaluate promising new technologies in the field of molecular diagnosis of overseas ventures
that do not have commercial distribution to Japan, and AXEL MARK will acquire domestic commercialization
rights and develop appropriate business partners. We believe that this partnership can build the collaborative
value chain in the molecular diagnosis market.
Hereafter, both companies aim to contribute to improve people’s healthy life expectancy by promoting the
spread of new medical diagnosis technologies.
https://www.axcelead-hd.com/wp-content/uploads/2021/04/ENG_AXELMARK_AXCELEAD2021.04.19.pdf

19th of April, 2021
AXEL MARK Inc.
Axcelead, Inc.
AXEL MARK and Axcelead have Agreed to Cooperate in
Product Evaluation & Domestic Logistics of Molecular Diagnostics Field
AXEL MARK Inc. (President & CEO, Hiroshi Matsukawa, TSE Mothers:3624, “Axcel Mark”) and Axcelead, Inc.
(President & CEO, Tomoyuki Fujisawa, “Axcelead”) today announced that they have agreed on a collaborative
partnership in product evaluation & domestic logistics of molecular diagnostics field.
AXEL MARK has previously made the disclosure of "The 22nd Acquisition and Cancellation of Stock
Acquisition Rights and the 1st Notice Regarding Changes in Use of Funds for Unsecured Convertible Bonds
with Stock Acquisition Rights” on March 26 2021, announced about our new entry into the healthcare
business, and this press release is an announcement regarding to it. Please see the following materials for
the information on AXEL MARK's entry into the healthcare business.
○Disclosure on 26th March, 2021
https://contents.xj-
storage.jp/xcontents/AS02626/59834c81/8587/4459/9a33/c4a07164fcd9/140120210326485155.pdf
The market is undergoing rapid expansion due to the unprecedented global demand for COVID-19 testing
via molecular methods, but the other segments, including cancer and various infectious disease, are also
experiencing significant growth. The global market for molecular diagnostics is expected to reach to the value
of more than $12bn. by 2024. ※
“Molecular diagnostics” is the diagnostic and screening process of infectious disease, cancer, and genetic
disease by analyzing proteins and nucleic acid（DNA and RNA）molecules in tissue or body fluid.
Disease identification is being utilized not only in medical site but also in private companies and home
diagnosis as it leads to early detection and treatment of diseases, and new technologies are being actively
developed worldwide.
In addition to the conventional major chemical analysis equipment, reagents, and scientific service
companies, start-up companies are also promoting the development of new technology for molecular
diagnosis, and test kits with various features have been commercialized, and new products will continue to be
released in the market from now on.
Axcelead will evaluate promising new technologies in the field of molecular diagnosis of overseas ventures
that do not have commercial distribution to Japan, and AXEL MARK will acquire domestic commercialization
rights and develop appropriate business partners. We believe that this partnership can build the collaborative
value chain in the molecular diagnosis market.
Hereafter, both companies aim to contribute to improve people’s healthy life expectancy by promoting the
spread of new medical diagnosis technologies.
https://www.axcelead-hd.com/wp-content/uploads/2021/04/ENG_AXELMARK_AXCELEAD2021.04.19.pdf

19th of April, 2021
AXEL MARK Inc.
Axcelead, Inc.
AXEL MARK and Axcelead have Agreed to Cooperate in
Product Evaluation & Domestic Logistics of Molecular Diagnostics Field
AXEL MARK Inc. (President & CEO, Hiroshi Matsukawa, TSE Mothers:3624, “Axcel Mark”) and Axcelead, Inc.
(President & CEO, Tomoyuki Fujisawa, “Axcelead”) today announced that they have agreed on a collaborative
partnership in product evaluation & domestic logistics of molecular diagnostics field.
AXEL MARK has previously made the disclosure of "The 22nd Acquisition and Cancellation of Stock
Acquisition Rights and the 1st Notice Regarding Changes in Use of Funds for Unsecured Convertible Bonds
with Stock Acquisition Rights” on March 26 2021, announced about our new entry into the healthcare
business, and this press release is an announcement regarding to it. Please see the following materials for
the information on AXEL MARK's entry into the healthcare business.
○Disclosure on 26th March, 2021
https://contents.xj-
storage.jp/xcontents/AS02626/59834c81/8587/4459/9a33/c4a07164fcd9/140120210326485155.pdf
The market is undergoing rapid expansion due to the unprecedented global demand for COVID-19 testing
via molecular methods, but the other segments, including cancer and various infectious disease, are also
experiencing significant growth. The global market for molecular diagnostics is expected to reach to the value
of more than $12bn. by 2024. ※
“Molecular diagnostics” is the diagnostic and screening process of infectious disease, cancer, and genetic
disease by analyzing proteins and nucleic acid（DNA and RNA）molecules in tissue or body fluid.
Disease identification is being utilized not only in medical site but also in private companies and home
diagnosis as it leads to early detection and treatment of diseases, and new technologies are being actively
developed worldwide.
In addition to the conventional major chemical analysis equipment, reagents, and scientific service
companies, start-up companies are also promoting the development of new technology for molecular
diagnosis, and test kits with various features have been commercialized, and new products will continue to be
released in the market from now on.
Axcelead will evaluate promising new technologies in the field of molecular diagnosis of overseas ventures
that do not have commercial distribution to Japan, and AXEL MARK will acquire domestic commercialization
rights and develop appropriate business partners. We believe that this partnership can build the collaborative
value chain in the molecular diagnosis market.
Hereafter, both companies aim to contribute to improve people’s healthy life expectancy by promoting the
spread of new medical diagnosis technologies.
https://www.axcelead-hd.com/wp-content/uploads/2021/04/ENG_AXELMARK_AXCELEAD2021.04.19.pdf

China conducts aerial bombing drill after US-Japan statement on Taiwan

19th of April, 2021
AXEL MARK Inc.
Axcelead, Inc.
AXEL MARK and Axcelead have Agreed to Cooperate in
Product Evaluation & Domestic Logistics of Molecular Diagnostics Field
AXEL MARK Inc. (President & CEO, Hiroshi Matsukawa, TSE Mothers:3624, “Axcel Mark”) and Axcelead, Inc.
(President & CEO, Tomoyuki Fujisawa, “Axcelead”) today announced that they have agreed on a collaborative
partnership in product evaluation & domestic logistics of molecular diagnostics field.
AXEL MARK has previously made the disclosure of "The 22nd Acquisition and Cancellation of Stock
Acquisition Rights and the 1st Notice Regarding Changes in Use of Funds for Unsecured Convertible Bonds
with Stock Acquisition Rights” on March 26 2021, announced about our new entry into the healthcare
business, and this press release is an announcement regarding to it. Please see the following materials for
the information on AXEL MARK's entry into the healthcare business.
○Disclosure on 26th March, 2021
https://contents.xj-
storage.jp/xcontents/AS02626/59834c81/8587/4459/9a33/c4a07164fcd9/140120210326485155.pdf
The market is undergoing rapid expansion due to the unprecedented global demand for COVID-19 testing
via molecular methods, but the other segments, including cancer and various infectious disease, are also
experiencing significant growth. The global market for molecular diagnostics is expected to reach to the value
of more than $12bn. by 2024. ※
“Molecular diagnostics” is the diagnostic and screening process of infectious disease, cancer, and genetic
disease by analyzing proteins and nucleic acid（DNA and RNA）molecules in tissue or body fluid.
Disease identification is being utilized not only in medical site but also in private companies and home
diagnosis as it leads to early detection and treatment of diseases, and new technologies are being actively
developed worldwide.
In addition to the conventional major chemical analysis equipment, reagents, and scientific service
companies, start-up companies are also promoting the development of new technology for molecular
diagnosis, and test kits with various features have been commercialized, and new products will continue to be
released in the market from now on.
Axcelead will evaluate promising new technologies in the field of molecular diagnosis of overseas ventures
that do not have commercial distribution to Japan, and AXEL MARK will acquire domestic commercialization
rights and develop appropriate business partners. We believe that this partnership can build the collaborative
value chain in the molecular diagnosis market.
Hereafter, both companies aim to contribute to improve people’s healthy life expectancy by promoting the
spread of new medical diagnosis technologies.
https://www.axcelead-hd.com/wp-content/uploads/2021/04/ENG_AXELMARK_AXCELEAD2021.04.19.pdf

19th of April, 2021
AXEL MARK Inc.
Axcelead, Inc.
AXEL MARK and Axcelead have Agreed to Cooperate in
Product Evaluation & Domestic Logistics of Molecular Diagnostics Field
AXEL MARK Inc. (President & CEO, Hiroshi Matsukawa, TSE Mothers:3624, “Axcel Mark”) and Axcelead, Inc.
(President & CEO, Tomoyuki Fujisawa, “Axcelead”) today announced that they have agreed on a collaborative
partnership in product evaluation & domestic logistics of molecular diagnostics field.
AXEL MARK has previously made the disclosure of "The 22nd Acquisition and Cancellation of Stock
Acquisition Rights and the 1st Notice Regarding Changes in Use of Funds for Unsecured Convertible Bonds
with Stock Acquisition Rights” on March 26 2021, announced about our new entry into the healthcare
business, and this press release is an announcement regarding to it. Please see the following materials for
the information on AXEL MARK's entry into the healthcare business.
○Disclosure on 26th March, 2021
https://contents.xj-
storage.jp/xcontents/AS02626/59834c81/8587/4459/9a33/c4a07164fcd9/140120210326485155.pdf
The market is undergoing rapid expansion due to the unprecedented global demand for COVID-19 testing
via molecular methods, but the other segments, including cancer and various infectious disease, are also
experiencing significant growth. The global market for molecular diagnostics is expected to reach to the value
of more than $12bn. by 2024. ※
“Molecular diagnostics” is the diagnostic and screening process of infectious disease, cancer, and genetic
disease by analyzing proteins and nucleic acid（DNA and RNA）molecules in tissue or body fluid.
Disease identification is being utilized not only in medical site but also in private companies and home
diagnosis as it leads to early detection and treatment of diseases, and new technologies are being actively
developed worldwide.
In addition to the conventional major chemical analysis equipment, reagents, and scientific service
companies, start-up companies are also promoting the development of new technology for molecular
diagnosis, and test kits with various features have been commercialized, and new products will continue to be
released in the market from now on.
Axcelead will evaluate promising new technologies in the field of molecular diagnosis of overseas ventures
that do not have commercial distribution to Japan, and AXEL MARK will acquire domestic commercialization
rights and develop appropriate business partners. We believe that this partnership can build the collaborative
value chain in the molecular diagnosis market.
Hereafter, both companies aim to contribute to improve people’s healthy life expectancy by promoting the
spread of new medical diagnosis technologies.
https://www.axcelead-hd.com/wp-content/uploads/2021/04/ENG_AXELMARK_AXCELEAD2021.04.19.pdf

19th of April, 2021
AXEL MARK Inc.
Axcelead, Inc.
AXEL MARK and Axcelead have Agreed to Cooperate in
Product Evaluation & Domestic Logistics of Molecular Diagnostics Field
AXEL MARK Inc. (President & CEO, Hiroshi Matsukawa, TSE Mothers:3624, “Axcel Mark”) and Axcelead, Inc.
(President & CEO, Tomoyuki Fujisawa, “Axcelead”) today announced that they have agreed on a collaborative
partnership in product evaluation & domestic logistics of molecular diagnostics field.
AXEL MARK has previously made the disclosure of "The 22nd Acquisition and Cancellation of Stock
Acquisition Rights and the 1st Notice Regarding Changes in Use of Funds for Unsecured Convertible Bonds
with Stock Acquisition Rights” on March 26 2021, announced about our new entry into the healthcare
business, and this press release is an announcement regarding to it. Please see the following materials for
the information on AXEL MARK's entry into the healthcare business.
○Disclosure on 26th March, 2021
https://contents.xj-
storage.jp/xcontents/AS02626/59834c81/8587/4459/9a33/c4a07164fcd9/140120210326485155.pdf
The market is undergoing rapid expansion due to the unprecedented global demand for COVID-19 testing
via molecular methods, but the other segments, including cancer and various infectious disease, are also
experiencing significant growth. The global market for molecular diagnostics is expected to reach to the value
of more than $12bn. by 2024. ※
“Molecular diagnostics” is the diagnostic and screening process of infectious disease, cancer, and genetic
disease by analyzing proteins and nucleic acid（DNA and RNA）molecules in tissue or body fluid.
Disease identification is being utilized not only in medical site but also in private companies and home
diagnosis as it leads to early detection and treatment of diseases, and new technologies are being actively
developed worldwide.
In addition to the conventional major chemical analysis equipment, reagents, and scientific service
companies, start-up companies are also promoting the development of new technology for molecular
diagnosis, and test kits with various features have been commercialized, and new products will continue to be
released in the market from now on.
Axcelead will evaluate promising new technologies in the field of molecular diagnosis of overseas ventures
that do not have commercial distribution to Japan, and AXEL MARK will acquire domestic commercialization
rights and develop appropriate business partners. We believe that this partnership can build the collaborative
value chain in the molecular diagnosis market.
Hereafter, both companies aim to contribute to improve people’s healthy life expectancy by promoting the
spread of new medical diagnosis technologies.
https://www.axcelead-hd.com/wp-content/uploads/2021/04/ENG_AXELMARK_AXCELEAD2021.04.19.pdf
https://www.axcelead-hd.com/

19th of April, 2021
AXEL MARK Inc.
Axcelead, Inc.
AXEL MARK and Axcelead have Agreed to Cooperate in
Product Evaluation & Domestic Logistics of Molecular Diagnostics Field
AXEL MARK Inc. (President & CEO, Hiroshi Matsukawa, TSE Mothers:3624, “Axcel Mark”) and Axcelead, Inc.
(President & CEO, Tomoyuki Fujisawa, “Axcelead”) today announced that they have agreed on a collaborative
partnership in product evaluation & domestic logistics of molecular diagnostics field.
AXEL MARK has previously made the disclosure of "The 22nd Acquisition and Cancellation of Stock
Acquisition Rights and the 1st Notice Regarding Changes in Use of Funds for Unsecured Convertible Bonds
with Stock Acquisition Rights” on March 26 2021, announced about our new entry into the healthcare
business, and this press release is an announcement regarding to it. Please see the following materials for
the information on AXEL MARK's entry into the healthcare business.
○Disclosure on 26th March, 2021
https://contents.xj-
storage.jp/xcontents/AS02626/59834c81/8587/4459/9a33/c4a07164fcd9/140120210326485155.pdf
The market is undergoing rapid expansion due to the unprecedented global demand for COVID-19 testing
via molecular methods, but the other segments, including cancer and various infectious disease, are also
experiencing significant growth. The global market for molecular diagnostics is expected to reach to the value
of more than $12bn. by 2024. ※
“Molecular diagnostics” is the diagnostic and screening process of infectious disease, cancer, and genetic
disease by analyzing proteins and nucleic acid（DNA and RNA）molecules in tissue or body fluid.
Disease identification is being utilized not only in medical site but also in private companies and home
diagnosis as it leads to early detection and treatment of diseases, and new technologies are being actively
developed worldwide.
In addition to the conventional major chemical analysis equipment, reagents, and scientific service
companies, start-up companies are also promoting the development of new technology for molecular
diagnosis, and test kits with various features have been commercialized, and new products will continue to be
released in the market from now on.
Axcelead will evaluate promising new technologies in the field of molecular diagnosis of overseas ventures
that do not have commercial distribution to Japan, and AXEL MARK will acquire domestic commercialization
rights and develop appropriate business partners. We believe that this partnership can build the collaborative
value chain in the molecular diagnosis market.
Hereafter, both companies aim to contribute to improve people’s healthy life expectancy by promoting the
spread of new medical diagnosis technologies.
https://www.axcelead-hd.com/wp-content/uploads/2021/04/ENG_AXELMARK_AXCELEAD2021.04.19.pdf

U.S. RECOGNIZES DEEP ECONOMIC AND COMMERCIAL TIES BETWEEN JAPAN AND CHINA AND RESPECTS SUGA'S DESIRE TO WALK A CAREFUL COURSE - OFFICIAL

PBoC Conducts 150Bln Yuan Of 1 Year MLF At 2.95%
PBoC Drains Medium Term Liquidity From Banking System

Japan Chief Cabinet Sec Kato: Expects To Vaccinate Elderly By End-June

San Francisco Federal Reserve President Daly says she expects a transitory rise in inflation - BBG